Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 2:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: IV Administration of Vancomycin Clear all
Completed Phase 3 Interventional Results available

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

NCT00091819
View directory record Official record
Conditions
Staphylococcal Skin Infection
Interventions
Telavancin, Vancomycin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
National City, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 8, 2026, 2:15 PM EDT
Completed Phase 3 Interventional Results available

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

NCT02814916
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
Interventions
Dalbavancin, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
0 Years to 17 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • La Palma, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 8, 2026, 2:15 PM EDT
Completed Phase 4 Interventional Results available

Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA

NCT01419184
View directory record Official record
Conditions
Staphylococcal Skin Infections
Interventions
Daptomycin, Vancomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
25
States / cities
Mobile, Alabama • Chula Vista, California • Escondido, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Sep 8, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

NCT00061633
View directory record Official record
Conditions
Infections, Gram-Positive Bacterial, Abscess, Burns, Cellulitis, Ulcer, Wound Infections
Interventions
Telavancin, Vancomycin or antistaphylococcal penicillin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 8, 2026, 2:15 PM EDT
Recruiting Not applicable Interventional

Real-component vs All-cement Articulating Spacers for Periprosthetic Knee Infection

NCT06293352
View directory record Official record
Conditions
Prosthetic-joint Infection, Knee Infection, Arthroplasty Complications, Joint Infection, Arthroplasty, Replacement, Knee
Interventions
All-cement articulating spacer, Durable, real-component articulating spacer, Rigid Spacer
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 8, 2026, 2:15 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus

NCT01645735
View directory record Official record
Conditions
Infections
Interventions
Ceftaroline fosamil, Ceftriaxone plus vancomycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Phoenix, Arizona • Sylmar, California • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2016 · Synced Sep 8, 2026, 2:15 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

IO Vancomycin Spine

NCT06748144
View directory record Official record
Conditions
Lumbar Fusion Surgery
Interventions
Intraosseous Vancomycin, Intravenous Vancomycin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 8, 2026, 2:15 PM EDT
Not listed Phase 4 Interventional

IO vs IV Vancomycin in Tourniquetless TKA

NCT05705843
View directory record Official record
Conditions
Infection, Surgical Site
Interventions
Intraosseous Vancomycin Injection, Intravenous Vancomycin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
19 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Sep 8, 2026, 2:15 PM EDT
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

Can Intraosseous Antibiotics Improve the Results of Irrigation & Debridement and Prosthetic Retention for PJI?

NCT03713528
View directory record Official record
Conditions
Joint Infection
Interventions
Intraoperative Intraosseous Vancomycin
Drug
Lead sponsor
OrthoCarolina Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
10
States / cities
San Francisco, California • Gainesville, Florida • Weston, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 8, 2026, 2:15 PM EDT
Completed Phase 4 Interventional Results available

Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol

NCT04042233
View directory record Official record
Conditions
Prosthetic Joint Infection, Vancomycin, Joint Diseases
Interventions
Experimental Intraosseous vancomycin 500mg in 250 mL NS, Standard IV administration of vancomycin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
19 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Sep 8, 2026, 2:15 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Outpatient Treatment of Gram Positive Wound Infections in the Diabetic Foot: A Pharmaco-economic Comparison of Daptomycin vs. Vancomycin Based Regimens

NCT01133600
View directory record Official record
Conditions
Diabetic Foot
Interventions
Cubicin, Vancomycin
Drug
Lead sponsor
Clinical Alliance for Research & Education - Infectious Diseases, LLC.
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Annandale, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2013 · Synced Sep 8, 2026, 2:15 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT01431339
View directory record Official record
Conditions
Abscess, Wound Infection, Surgical Site Infection, Cellulitis
Interventions
IV Dalbavancin, Vancomycin/Linezolid
Drug
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Industry
Eligibility
18 Years to 85 Years
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
30
States / cities
Montgomery, Alabama • Anaheim, California • Buena Park, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Sep 8, 2026, 2:15 PM EDT
Completed Phase 4 Interventional Results available

Impact of Oral Antibiotic Treatment on C. Difficile

NCT02057198
View directory record Official record
Conditions
C. Difficile, Diarrhea, Enterocolitis
Interventions
Fidaxomicin, Metronidazole, Vancomycin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Sep 8, 2026, 2:15 PM EDT
Terminated Phase 3 Interventional Results available

Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections

NCT00108433
View directory record Official record
Conditions
Bacteremia, Gram-Positive Bacterial Infections
Interventions
Cefazolin IV, Linezolid IV, Vancomycin (IV)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Sep 8, 2026, 2:15 PM EDT
Completed Phase 3 Interventional Results available

Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)

NCT03182907
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Bezlotoxumab, Placebo, Antibacterial drug treatment (ABD)
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Year to 17 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
21
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 8, 2026, 2:15 PM EDT
Terminated Early Phase 1 Interventional

Patients Response to Early Switch To Oral:Osteomyelitis Study

NCT02099240
View directory record Official record
Conditions
Osteomyelitis
Interventions
oral antibiotics, intravenous antibiotics
Drug · Procedure
Lead sponsor
Julio Ramirez
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Sep 8, 2026, 2:15 PM EDT
Terminated Phase 4 Interventional Results available

Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment

NCT01104662
View directory record Official record
Conditions
Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia, Renal Impairment
Interventions
Vancomycin, Daptomycin, Semi-Synthetic Penicillin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Azusa, California • Los Angeles, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Sep 8, 2026, 2:15 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Vancomycin in TKAs

NCT07282782
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Vancomycin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 8, 2026, 2:15 PM EDT
Completed Phase 2 Interventional

TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection

NCT00442832
View directory record Official record
Conditions
Staphylococcal Skin Infection
Interventions
TD-1792, Vancomycin
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
National City, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 8, 2026, 2:15 PM EDT
Terminated Phase 2 Interventional Results available

Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

NCT02732327
View directory record Official record
Conditions
Neoplasms, Febrile Neutropenia
Interventions
CAZ-AVI, Vancomycin, Linezolid, Cefepime, Meropenem, Piperacillin/tazobactam
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 8, 2026, 2:15 PM EDT
Recruiting Phase 3 Interventional

Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT 2

NCT04678154
View directory record Official record
Conditions
Post Operative Surgical Site Infection
Interventions
Standard of care, Vancomycin and Tobramycin
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 64 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
31
States / cities
Redwood City, California • San Francisco, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 8, 2026, 2:15 PM EDT
Completed Phase 3 Interventional Results available

Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection

NCT01252732
View directory record Official record
Conditions
Wound Infection, Abscess, Systemic Inflammation, Cellulitis
Interventions
Single-Dose IV Oritavancin Diphosphate, IV Vancomycin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,019 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
La Mesa, California
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 8, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Results available

Study of Debio 1450 for Bacterial Skin Infections

NCT02426918
View directory record Official record
Conditions
Bacterial Infections
Interventions
Debio 1450 IV, Debio 1450 Oral, Linezolid, Debio 1450 Oral Placebo, Linezolid Placebo, Vancomycin IV
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
22
States / cities
Anaheim, California • Buena Park, California • Chula Vista, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Sep 8, 2026, 2:15 PM EDT
Completed Phase 1 Interventional

Vancomycin Tissue Concentrations by Bier Block or Intravenous Administration

NCT04673877
View directory record Official record
Conditions
Infection, Hand Injury Wrist, Hand Injuries, Hand Injuries and Disorders, Hand Arthritis
Interventions
Systemic IV Vancomycin, Bier Block, Vancomycin
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Sep 8, 2026, 2:15 PM EDT